William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.
|Videos|December 17, 2020
Dr. Ramaprasad Srinivasan highlights the latest treatment advances in kidney cancer
Author(s)Urology Times staff
The comprehensive review includes key developments in both clear cell and non-clear cell histology.
Advertisement
Ramaprasad Srinivasan, MD, PhD, Urologic Oncology Branch, National Cancer Institute, summarizes the latest advances in the treatment paradigm for patients with renal cell carcinoma (RCC).
At the 2020 Society of Urologic Oncology Annual Meeting, Srinivasan shared data on one of these advances: a
In this video, Srinivasan provides a comprehensive review the latest breakthroughs in all areas of RCC, including both clear cell and non-clear cell histology.
Advertisement
Related to this article
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5